Compare Flex Ltd (FLEX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flex Ltd vs Repligen Corporation Common Stock — how do they compare? Flex Ltd trades at $97.49 (market cap $40.97B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Flex Ltd is far larger — about 3.7× Repligen Corporation Common Stock's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Flex Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Flex Ltd for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| FLEX | RGEN | |
|---|---|---|
Market Cap | $40.97B | $11.14B |
Volume | 5,533,554 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $162.07 | $194.57 |
52-Week Low | $54.51 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $44.06B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLEX trades at $110.88, down 5.42% over the past day, amid a broader market pullback. The stock maintains a bullish technical trend with strong analyst support, including a consensus price target of $147.50. Recent acquisitions like EPC Power and the planned spin-off of Axiom highlight strategic moves to capitalize on AI data center and power infrastructure growth. Fundamentals show solid profitability with a net income margin of 3.32% and revenue growth to $29.3B projected for 2026.
The outlook for FLEX is positive, driven by expansion in AI infrastructure and consistent earnings beats. Investment opportunities include potential upside from the Axiom spin-off and continued demand in cloud and power sectors. Key risks involve integration challenges from acquisitions, competitive pressures, and market volatility affecting valuation multiples.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flex Ltd
Flex provides design, engineering, manufacturing, supply chain, and logistics services for technology products. It serves industries including cloud, data centers, communications, automotive, healthcare, and industrials.
Read more on FLEX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
